eLife (Nov 2021)

ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer

  • Wentong Fang,
  • Chengheng Liao,
  • Rachel Shi,
  • Jeremy M Simon,
  • Travis S Ptacek,
  • Giada Zurlo,
  • Youqiong Ye,
  • Leng Han,
  • Cheng Fan,
  • Lei Bao,
  • Christopher Llynard Ortiz,
  • Hong-Rui Lin,
  • Ujjawal Manocha,
  • Weibo Luo,
  • Yan Peng,
  • William Y Kim,
  • Lee-Wei Yang,
  • Qing Zhang

DOI
https://doi.org/10.7554/eLife.70412
Journal volume & issue
Vol. 10

Abstract

Read online

Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease, which warrants the critical need to identify new therapeutic targets. We show that Zinc Fingers and Homeoboxes 2 (ZHX2) is amplified or overexpressed in TNBC cell lines and patients. Functionally, depletion of ZHX2 inhibited TNBC cell growth and invasion in vitro, orthotopic tumor growth, and spontaneous lung metastasis in vivo. Mechanistically, ZHX2 bound with hypoxia-inducible factor (HIF) family members and positively regulated HIF1α activity in TNBC. Integrated ChIP-seq and gene expression profiling demonstrated that ZHX2 co-occupied with HIF1α on transcriptionally active promoters marked by H3K4me3 and H3K27ac, thereby promoting gene expression. Among the identified ZHX2 and HIF1α coregulated genes, overexpression of AP2B1, COX20, KDM3A, or PTGES3L could partially rescue TNBC cell growth defect by ZHX2 depletion, suggested that these downstream targets contribute to the oncogenic role of ZHX2 in an accumulative fashion. Furthermore, multiple residues (R491, R581, and R674) on ZHX2 are important in regulating its phenotype, which correspond with their roles on controlling ZHX2 transcriptional activity in TNBC cells. These studies establish that ZHX2 activates oncogenic HIF1α signaling, therefore serving as a potential therapeutic target for TNBC.

Keywords